Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 52

1.

Everolimus in the management of metastatic neuroendocrine tumours.

Chan DL, Segelov E, Singh S.

Therap Adv Gastroenterol. 2017 Jan;10(1):132-141. doi: 10.1177/1756283X16674660. Epub 2016 Oct 25. Review.

2.

Uncommon Anal Neoplasms.

Roy AC, Wattchow D, Astill D, Singh S, Pendlebury S, Gormly K, Segelov E.

Surg Oncol Clin N Am. 2017 Jan;26(1):143-161. doi: 10.1016/j.soc.2016.07.009. Review.

PMID:
27889033
3.

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.

Kerr RS, Love S, Segelov E, Johnstone E, Falcon B, Hewett P, Weaver A, Church D, Scudder C, Pearson S, Julier P, Pezzella F, Tomlinson I, Domingo E, Kerr DJ.

Lancet Oncol. 2016 Nov;17(11):1543-1557. doi: 10.1016/S1470-2045(16)30172-3. Epub 2016 Sep 19.

PMID:
27660192
4.

TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer.

Ferraro D, Goldstein D, O'Connell RL, Zalcberg JR, Sjoquist KM, Tebbutt NC, Grimison P, McLachlan S, Lipton LL, Vasey P, Gebski VJ, Aiken C, Cronk M, Ng S, Karapetis CS, Shannon J; behalf of the the Australasian Gastro-Intestinal Trials Group..

Cancer Chemother Pharmacol. 2016 Aug;78(2):361-7. doi: 10.1007/s00280-016-3089-4. Epub 2016 Jun 22.

PMID:
27335026
5.

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.

Segelov E, Waring P, Desai J, Wilson K, Gebski V, Thavaneswaran S, Elez E, Underhill C, Pavlakis N, Chantrill L, Nott L, Jefford M, Khasraw M, Day F, Wasan H, Ciardiello F, Karapetis C, Joubert W, van Hazel G, Haydon A, Price T, Tejpar S, Tebbutt N, Shapiro J.

BMC Cancer. 2016 May 31;16:339. doi: 10.1186/s12885-016-2389-8.

6.

Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus.

Singh S, Asa SL, Dey C, Kennecke H, Laidley D, Law C, Asmis T, Chan D, Ezzat S, Goodwin R, Mete O, Pasieka J, Rivera J, Wong R, Segelov E, Rayson D.

Cancer Treat Rev. 2016 Jun;47:32-45. doi: 10.1016/j.ctrv.2016.05.003. Epub 2016 May 17. Review.

PMID:
27236421
7.

Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.

Segelov E, Thavaneswaran S, Waring PM, Desai J, Robledo KP, Gebski VJ, Elez E, Nott LM, Karapetis CS, Lunke S, Chantrill LA, Pavlakis N, Khasraw M, Underhill C, Ciardiello F, Jefford M, Wasan H, Haydon A, Price TJ, van Hazel G, Wilson K, Simes J, Shapiro JD.

J Clin Oncol. 2016 Jul 1;34(19):2258-64. doi: 10.1200/JCO.2015.65.6843. Epub 2016 Apr 25.

PMID:
27114605
8.

Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015.

Price TJ, Thavaneswaran S, Burge M, Segelov E, Haller DG, Punt CJ, Arnold D, Karapetis CS, Tebbutt NC, Pavlakis N, Gibbs P, Shapiro JD.

Expert Rev Anticancer Ther. 2016 May;16(5):557-71. doi: 10.1586/14737140.2016.1170594.

PMID:
27010906
9.

JRK is a positive regulator of ╬▓-catenin transcriptional activity commonly overexpressed in colon, breast and ovarian cancer.

Pangon L, Ng I, Giry-Laterriere M, Currey N, Morgan A, Benthani F, Tran PN, Al-Sohaily S, Segelov E, Parker BL, Cowley MJ, Wright DC, St Heaps L, Carey L, Rooman I, Kohonen-Corish MR.

Oncogene. 2016 Jun 2;35(22):2834-41. doi: 10.1038/onc.2015.347. Epub 2015 Oct 12.

PMID:
26455321
10.

Correction: Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.

Chan DL, Pavlakis N, Shapiro J, Price TJ, Karapetis CS, Tebbutt NC, Segelov E.

PLoS One. 2015 Sep 25;10(9):e0138916. doi: 10.1371/journal.pone.0138916. eCollection 2015. No abstract available.

11.

Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.

Chan DL, Pavlakis N, Shapiro J, Price TJ, Karapetis CS, Tebbutt NC, Segelov E.

PLoS One. 2015 Aug 14;10(8):e0135599. doi: 10.1371/journal.pone.0135599. eCollection 2015. Erratum in: PLoS One. 2015;10(9):e0138916.

12.

Describing Patterns of Care in Pancreatic Cancer: A Population-Based Study.

Burmeister EA, O╩╝Connell DL, Beesley VL, Goldstein D, Gooden HM, Janda M, Jordan SJ, Merrett ND, Payne ME, Wyld D, Neale RE; Pancreatic Cancer Patterns of Care Study Group..

Pancreas. 2015 Nov;44(8):1259-65. doi: 10.1097/MPA.0000000000000384.

PMID:
26262591
14.

Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients.

Soon SS, Chia WK, Chan ML, Ho GF, Jian X, Deng YH, Tan CS, Sharma A, Segelov E, Mehta S, Ali R, Toh HC, Wee HL.

PLoS One. 2014 Sep 24;9(9):e107866. doi: 10.1371/journal.pone.0107866. eCollection 2014.

15.

Human papillomavirus 16-specific T-cell responses and spontaneous regression of anal high-grade squamous intraepithelial lesions.

Tong WW, Shepherd K, Garland S, Meagher A, Templeton DJ, Fairley CK, Jin F, Poynten IM, Zaunders J, Hillman RJ, Grulich AE, Kelleher AD, Carr A; Study of the Prevention of Anal Cancer (SPANC) team..

J Infect Dis. 2015 Feb 1;211(3):405-15. doi: 10.1093/infdis/jiu461. Epub 2014 Aug 19.

PMID:
25139018
16.

Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013.

Price TJ, Segelov E, Burge M, Haller DG, Tebbutt NC, Karapetis CS, Punt CJ, Pavlakis N, Arnold D, Gibbs P, Shapiro JD.

Expert Rev Anticancer Ther. 2014 Dec;14(12):1477-93. doi: 10.1586/14737140.2014.949678. Epub 2014 Aug 20. Review.

PMID:
25138900
17.

The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials.

Segelov E, Chan D, Shapiro J, Price TJ, Karapetis CS, Tebbutt NC, Pavlakis N.

Br J Cancer. 2014 Sep 9;111(6):1122-31. doi: 10.1038/bjc.2014.404. Epub 2014 Jul 29. Review.

18.

Physical activity and fitness in women with metastatic breast cancer.

Yee J, Davis GM, Beith JM, Wilcken N, Currow D, Emery J, Phillips J, Martin A, Hui R, Harrison M, Segelov E, Kilbreath SL.

J Cancer Surviv. 2014 Dec;8(4):647-56. doi: 10.1007/s11764-014-0378-y. Epub 2014 Jul 2.

PMID:
24986228
19.

A case-control study of the role of human papillomavirus in oesophageal squamous cell carcinoma in australia.

Liyanage SS, Segelov E, Malik A, Garland SM, Tabrizi SN, Cummins E, Seale H, Rahman B, Moa A, Barbour AP, Crowe PJ, MacIntyre CR.

J Oncol. 2014;2014:236482. doi: 10.1155/2014/236482. Epub 2014 Apr 28.

20.

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.

Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A; IBIS-II investigators..

Lancet. 2014 Mar 22;383(9922):1041-8. doi: 10.1016/S0140-6736(13)62292-8. Epub 2013 Dec 12. Erratum in: Lancet. 2014 Mar 22;383(9922):1040.

Supplemental Content

Loading ...
Support Center